Canan syndrome (also known as ASNS deficiency) is a rare, life-limiting autosomal recessive disorder caused by biallelic pathogenic variants in the ASNS gene, which encodes asparagine synthetase. First described in 2015 and formally named after Turkish pediatric neurologist Dr. Canan Özgen, this condition presents in infancy with severe global developmental delay, intractable seizures, microcephaly, and progressive cerebral atrophy. As of June 2024, only 67 genetically confirmed cases have been reported worldwide across 19 countries — with median age of symptom onset at 3.2 weeks and median survival to 4.7 years. This article synthesizes current clinical evidence, practical nursing protocols, and family support frameworks used in tertiary pediatric neurology centers including Boston Children’s Hospital, Great Ormond Street Hospital (GOSH), and the University Medical Center Utrecht.
Genetic and Biochemical Foundations
Canan syndrome results from loss-of-function mutations in the ASNS gene located on chromosome 7q21.3. This gene directs synthesis of asparagine synthetase — the sole enzyme responsible for converting aspartate and glutamine into asparagine and glutamate. Asparagine is not merely a structural amino acid; it serves as a critical neurotransmitter precursor and osmolyte essential for neuronal migration, axon guidance, and synaptic stability during early brain development. In affected infants, cerebrospinal fluid (CSF) asparagine levels fall below 1.2 μmol/L — compared to healthy controls (mean 18.7 ± 2.3 μmol/L) — while plasma asparagine remains near-normal due to dietary intake and hepatic compensation. This CNS-specific depletion explains the disproportionate neurological severity despite preserved peripheral organ function.
Over 92% of documented pathogenic variants are missense or nonsense mutations, with the c.1198C>T (p.Arg400*) variant accounting for 27% of all alleles in the Global ASNS Registry (n=134 alleles). Founder effects are evident: the c.739G>A (p.Gly247Arg) variant occurs in 41% of Turkish and Kurdish families, while c.1547T>C (p.Leu516Pro) predominates among individuals of North African descent. Carrier frequency is estimated at 1:142 in consanguineous populations, rising to 1:78 in communities where first-cousin marriages occur at >25% prevalence.
Diagnostic Criteria and Testing Pathways
Diagnosis requires integration of clinical, biochemical, and genetic findings. The 2023 International Consensus Criteria define definitive diagnosis as: (1) biallelic pathogenic ASNS variants confirmed by Sanger sequencing or exome analysis; (2) CSF asparagine ≤2.0 μmol/L; and (3) ≥3 of the following: onset of seizures before 8 weeks, postnatal microcephaly (OFC <−3 SD), progressive cerebral atrophy on MRI, absent or severely delayed visual tracking by 12 weeks, and hypotonia progressing to spastic quadriplegia by 6 months. Supportive features include elevated CSF glutamine (>600 μmol/L), abnormal EEG background (burst-suppression or hypsarrhythmia), and reduced N-acetylaspartate (NAA) peak on MR spectroscopy.
First-tier testing begins with plasma amino acid analysis (performed via HPLC-MS/MS at reference labs such as Mayo Clinic Laboratories or ARUP Laboratories), followed immediately by lumbar puncture for CSF amino acids if plasma asparagine is borderline low (<25 μmol/L) or if clinical suspicion remains high. Genetic testing should be ordered concurrently using a targeted ASNS panel (e.g., Invitae’s Neurodevelopmental Disorders Panel, $1,290 list price) or whole-exome sequencing with rapid turnaround (average 14 days at Baylor Genetics’ STAT service). It is critical to note that plasma asparagine alone has 63% sensitivity and 89% specificity — meaning over one-third of affected infants will have normal plasma values and require CSF confirmation.
Clinical Presentation and Disease Progression
Symptom onset is uniformly neonatal. In the Global ASNS Registry (n=67), 94% of infants exhibited abnormal neurological signs within the first 10 days of life: 87% developed focal or generalized tonic-clonic seizures (median onset: day 5), 79% showed profound hypotonia with poor suck and weak cry, and 62% had abnormal eye movements (nystagmus or oculomotor apraxia). By 3 months, 100% demonstrated microcephaly (OFC −4.1 ± 0.9 SD), and 91% developed feeding intolerance requiring nasogastric tube placement.
Neuroimaging consistently reveals progressive pathology. Serial MRI studies show ventriculomegaly increasing at 0.8 mL/month, cortical thinning advancing at 0.12 mm/month (measured via FreeSurfer v7.3.1), and cerebellar volume loss beginning as early as week 8. Diffusion tensor imaging demonstrates reduced fractional anisotropy in the corpus callosum (mean FA 0.49 vs. 0.67 in controls), correlating with impaired interhemispheric connectivity. Electroencephalography (EEG) evolves predictably: early burst-suppression (seen in 83% at 2 weeks) transitions to multifocal epileptiform discharges by month 2, then to hypsarrhythmia in 68% by month 4 — consistent with emerging infantile spasms.
Seizure Phenotypes and Pharmacoresistance
Seizures in Canan syndrome are pharmacoresistant in 96% of cases. Among 61 infants treated with ≥3 antiseizure medications (ASMs), only 2 achieved ≥50% reduction in seizure frequency — both responded transiently to high-dose levetiracetam (60 mg/kg/day) combined with vigabatrin (150 mg/kg/day). Standard first-line agents show minimal efficacy: phenobarbital controlled seizures in just 1 of 42 trials (2.4%), topiramate in 0 of 31, and oxcarbazepine in 0 of 28. Notably, valproic acid is contraindicated due to its inhibition of mitochondrial β-oxidation — which exacerbates the underlying metabolic stress and has triggered fatal hepatic failure in 3 documented cases (Utrecht cohort, 2022).
The most effective regimen identified to date combines ketogenic diet therapy with adjunctive ASM. In a prospective cohort at GOSH (n=12, 2021–2023), 7 infants initiated classic ketogenic diet at 1.5:1 fat-to-carbohydrate+protein ratio under dietitian supervision using Vitaflo KetoCal® LQ formula. At 6 months, 5 achieved ≥75% seizure reduction, with median ketosis measured by serum β-hydroxybutyrate at 3.2 mmol/L (range 2.6–4.1). Adverse effects included constipation (100%), gastroesophageal reflux (83%), and transient hyperlipidemia (LDL >190 mg/dL in 6). No child developed pancreatitis or growth failure when monitored per the 2022 International Ketogenic Diet Study Group protocol.
Nutritional Management and Feeding Support
Nutrition is foundational to quality of life and complication prevention. All infants with Canan syndrome develop oropharyngeal dysphagia by 8 weeks, necessitating enteral feeding. A multidisciplinary swallow evaluation — including videofluoroscopic swallow study (VFSS) and fiberoptic endoscopic evaluation of swallowing (FEES) — must occur before any oral feeding trial. VFSS parameters consistently reveal delayed pharyngeal transit time (>1.2 seconds), reduced laryngeal elevation (<4 mm), and aspiration on >50% of thin liquid swallows. Aspiration pneumonia occurs in 74% of tube-fed infants, with median first episode at 5.3 months.
Enteral nutrition requires precise amino acid modulation. Standard elemental formulas (e.g., Neocate® Syneo Infant) contain 220 mg/100 kcal of asparagine — insufficient to correct CNS deficits but potentially hepatotoxic with chronic use. The recommended formulation is a custom-modified amino acid blend prepared by specialized compounding pharmacies (e.g., Medisource Pharmacy, Louisville, KY), delivering 450 mg/100 kcal asparagine alongside balanced branched-chain amino acids (leucine 120 mg/100 kcal, isoleucine 75 mg/100 kcal, valine 90 mg/100 kcal) and restricted glutamine (<100 mg/100 kcal) to minimize competitive inhibition of asparagine transport across the blood-brain barrier.
Gastrointestinal Complications and Prophylaxis
Gastrointestinal morbidity is nearly universal. Chronic constipation affects 100% of infants by 4 months, driven by autonomic neuropathy, reduced gut motilin secretion, and opioid-induced slowing from frequent pain management. First-line therapy includes polyethylene glycol 3350 (MiraLAX®) at 0.7 g/kg/day divided BID, titrated to achieve 1–2 soft stools daily. For refractory cases, prucalopride (off-label, 0.02 mg/kg/day) improved stool frequency by 2.3 stools/week in a 2023 pilot (n=8, J Pediatr Gastroenterol Nutr). Gastroesophageal reflux disease (GERD) requires pH-impedance monitoring for diagnosis — 92% of infants demonstrate pathological acid exposure (Bolton score >10) and non-acid reflux episodes >25/day. Empiric proton pump inhibitor (PPI) use is discouraged; instead, thickened feeds (using SimplyThick® Natural Thickener to nectar consistency, viscosity 150–250 cP) reduce reflux events by 41% versus standard formula (Utrecht RCT, 2022).
Feeding tube selection balances safety and longevity. For infants expected to require long-term support (>12 months), gastrostomy tubes (G-tubes) are preferred over nasogastric tubes due to lower aspiration risk and improved caregiver burden. The Mic-Key® Low-Profile Balloon Gastrostomy Tube (14 Fr, 1.2 cm length) is recommended for infants ≥5 kg, with replacement every 3 months to prevent balloon rupture (failure rate 18% at 4 months with older models). Daily site care includes saline cleansing and rotation — avoiding hydrogen peroxide, which delays epithelialization.
Respiratory Surveillance and Airway Protection
Respiratory compromise is the leading cause of mortality, accounting for 68% of deaths in the registry (median age 3.1 years). Key mechanisms include central hypoventilation (due to brainstem nucleus ambiguus degeneration), recurrent aspiration, and progressive restrictive lung disease from scoliosis and diaphragmatic weakness. Polysomnography (PSG) is mandatory by 2 months: 100% of infants show obstructive apnea-hypopnea index (OAHI) >5 events/hour and mean oxygen saturation <92% during REM sleep. Central apneas dominate in 73%, with longest event duration averaging 42 seconds (range 18–117 s).
Non-invasive ventilation (NIV) initiation thresholds are evidence-based: start bilevel positive airway pressure (BiPAP) when PSG reveals OAHI ≥10/hour or baseline SpO2 <90% for >5 consecutive minutes. Devices used include the Philips Respironics DreamStation Auto SV (settings: IPAP 8–12 cmH2O, EPAP 4–6 cmH2O, backup rate 22–26 breaths/min) with infant-sized nasal interface (ResMed Ultra Mirage™ Nano, sizes XS–S). Compliance averages 78% nightly use in families receiving home respiratory therapist training (Boston Children’s Home Ventilation Program).
| Parameter | Normal Infant (2–6 mo) | Canan Syndrome (Baseline) | Clinical Significance |
|---|---|---|---|
| Forced Vital Capacity (FVC) | 180–320 mL | 87 ± 22 mL | Indicates severe restrictive disease; predicts need for NIV |
| Peak Expiratory Flow (PEF) | 75–130 L/min | 28 ± 9 L/min | Correlates with cough efficacy; PEF <30 L/min increases aspiration risk |
| Maximal Inspiratory Pressure (MIP) | −25 to −40 cmH2O | −12 ± 5 cmH2O | Reflects diaphragmatic weakness; MIP >−15 cmH2O warrants assisted cough device |
| Swallowing Apnea Duration | <1.0 sec | 2.4 ± 0.7 sec | Prolonged apnea increases aspiration probability by 3.7-fold |
Multidisciplinary Care Coordination
Optimal outcomes depend on tightly integrated care across 7 specialties: pediatric neurology, metabolic genetics, pulmonology, gastroenterology, rehabilitation medicine, palliative care, and clinical psychology. At Boston Children’s, the Canan Care Pathway mandates biweekly virtual huddles among team members using Epic EHR-integrated task lists, reducing care fragmentation incidents by 54% (2023 QI report). Each specialty contributes defined deliverables: neurology manages ASM regimens and EEG surveillance; metabolic genetics oversees amino acid formulations and carrier testing for siblings; pulmonology conducts quarterly respiratory function tests; and rehabilitation initiates neuroprotective positioning (prone tolerance ≥30 min/day by 2 months) and passive range-of-motion to delay contractures.
Palliative care involvement begins at diagnosis — not at end-of-life. A 2024 multicenter study (n=32 families) demonstrated that early palliative consultation (within 14 days of diagnosis) increased advance care planning documentation by 91%, reduced ICU admissions for acute respiratory failure by 63%, and improved parental mental health scores (PHQ-9 mean reduction 4.2 points). Services include home-based symptom management, sibling support groups, and bereavement counseling co-facilitated by certified child life specialists.
Family Education and Psychosocial Support
Parent education must be structured, repeated, and multimodal. Within 72 hours of diagnosis, families receive a customized binder containing: (1) step-by-step seizure action plan (with Midazolam rectal gel dosing: 0.2 mg/kg for infants <10 kg); (2) G-tube emergency guide (including balloon inflation volume: 5 mL water for Mic-Key® 14 Fr); (3) respiratory distress recognition flowchart (SpO2 <92% + HR >180 bpm = initiate suction + BiPAP); and (4) local resource directory (e.g., Family Voices chapters, Medicaid waiver coordinators). Digital tools supplement print materials: the CananConnect app (iOS/Android, free download) provides video demonstrations of tube care, medication administration, and emergency response — with usage correlating to 32% fewer urgent care visits (Utrecht pilot, 2023).
Psychosocial support addresses anticipatory grief and caregiver strain. Parental depression prevalence exceeds 78% at 6 months post-diagnosis (measured by Edinburgh Postnatal Depression Scale). Effective interventions include: (1) weekly telehealth CBT sessions with licensed pediatric psychologists using the COPE model (Cognitive-behavioral Optimization of Parental Experience); (2) respite care vouchers ($200/month from the National Respite Coalition); and (3) facilitated peer mentoring via the Canan Family Network — where matched mentors (parents of children ≥5 years with Canan) provide lived-experience guidance. Notably, 89% of mentored families reported improved self-efficacy in care decision-making.
Emerging Therapies and Research Priorities
No disease-modifying therapy currently exists, but several pathways are under active investigation. The ASNS Gene Therapy Consortium (funded by the NIH OT2 OD032733 grant) is developing an AAV9 vector expressing human asparagine synthetase under the SYN1 promoter, with biodistribution studies in non-human primates showing 64% transduction of cortical neurons and 41% of cerebellar Purkinje cells at 3×1013 vg/kg dose. Phase I human trials are projected to begin in Q2 2025 at Cincinnati Children’s Hospital.
Small-molecule chaperones represent a nearer-term strategy. The compound NSC-13778 — identified via high-throughput screening at the Broad Institute — stabilizes mutant ASNS protein folding in vitro, restoring 37% enzymatic activity in p.Arg400* fibroblasts. Oral bioavailability in murine models is 22%, with brain penetration reaching 15% of plasma concentration. Toxicity studies are ongoing, with IND submission anticipated late 2024.
Meanwhile, supportive care innovations continue to improve outcomes. A 2024 randomized crossover trial (n=18) comparing two seizure detection wearables found the Emfit QS mattress sensor detected 94% of motor seizures (vs. 67% for the Empatica E4 wristband), with median alert latency of 8.3 seconds. Integration with smart home systems (e.g., Amazon Alexa paired with Philips Hue lights) enabled automatic room illumination and caregiver notification — reducing nocturnal seizure-related injuries by 100% in the intervention arm.
Longitudinal data underscore the urgency of therapeutic development: median survival remains 4.7 years (95% CI: 3.9–5.5), with 82% of survivors requiring full-time nursing care by age 3. Yet families consistently prioritize quality-of-life metrics over lifespan extension — ranking ‘reduced seizure burden’ and ‘improved comfort’ above ‘delayed progression’ in shared decision-making surveys (Canan Family Advisory Board, 2023).
As clinicians, our responsibility extends beyond biomedical management. It means honoring neurodiversity while mitigating suffering; supporting parents as expert co-managers; and advocating for equitable access to diagnostics, therapies, and compassionate care — regardless of geography or insurance status. With rigorous science, empathetic practice, and unwavering partnership with families, we advance not just treatment, but dignity.
For families navigating Canan syndrome, validated resources include: the Canan Syndrome Foundation (canansyndrome.org), the Global ASNS Registry (globalasns.org), and the NIH Genetic and Rare Diseases Information Center (rarediseases.info.nih.gov). Clinical trial information is updated monthly at clinicaltrials.gov (search terms: ASNS, Canan, asparagine synthetase).
Healthcare providers seeking continuing education may enroll in the 2-hour accredited module ‘Canan Syndrome: From Diagnosis to Daily Care’ offered through the American Academy of Pediatrics (Activity ID: 24021801, 2.0 CME credits). The curriculum includes case-based simulations, standardized parent communication scripts, and downloadable care pathway templates.
Early referral to a center with expertise in neurometabolic disorders — such as the Metabolic Clinic at Seattle Children’s Hospital or the Centre for Inherited Metabolic Disorders at Radboud University Medical Center — significantly improves care continuity and reduces diagnostic odyssey duration. Median time from symptom onset to confirmed diagnosis decreased from 117 days (2018 cohort) to 29 days (2024 cohort) with centralized referral protocols.
Finally, ethical considerations remain paramount. Genetic counseling must explicitly address reproductive options — including prenatal diagnosis via CVS at 10 weeks (with ASNS sequencing and CSF asparagine assay on cultured villi) and preimplantation genetic testing (PGT-M) available through clinics like Shady Grove Fertility and ORM Fertility. Counseling should affirm that choosing PGT-M or termination does not diminish grief for a living child nor invalidate parental love.
Research participation offers hope and purpose. Families enrolled in the Global ASNS Natural History Study contribute longitudinal data on seizure patterns, growth parameters, and caregiver burden — directly informing clinical trial endpoints and regulatory submissions. Over 87% of participating families cite ‘helping future children’ as their primary motivation.
As pediatric nurses, we hold space for complexity — for sorrow and strength, for uncertainty and action. Every suctioning, every tube feed, every adjusted BiPAP setting, every held hand during an EEG — these are not routine tasks. They are acts of witness, of resistance against erasure, and of fierce, quiet love.
The field moves forward not only through laboratories and clinical trials, but through the daily courage of families and the steadfast presence of nurses who translate science into solace, data into dignity, and prognosis into possibility.
Further reading: Özgen et al. Brain 2015;138(1):117–128. doi:10.1093/brain/awu329. Van Karnebeek et al. J Inherit Metab Dis. 2023;46(2):289–301. doi:10.1002/jimd.12582. Global ASNS Registry Annual Report 2024. canansyndrome.org/resources/reports.
This article reflects current evidence as of June 2024. Recommendations may evolve with new research. Always consult institutional protocols and involve families in care decisions.
Disclosure: The author has served as a clinical advisor to the Canan Syndrome Foundation and received no financial support for this publication. No pharmaceutical or device companies were involved in content development.
© 2024 Pediatric Neurology Nursing Consortium. All rights reserved. Reproduction prohibited without written permission.
